EP3390635A4 - Antisense oligomers for the treatment of a tuberous sclerosis complex - Google Patents

Antisense oligomers for the treatment of a tuberous sclerosis complex Download PDF

Info

Publication number
EP3390635A4
EP3390635A4 EP16876615.2A EP16876615A EP3390635A4 EP 3390635 A4 EP3390635 A4 EP 3390635A4 EP 16876615 A EP16876615 A EP 16876615A EP 3390635 A4 EP3390635 A4 EP 3390635A4
Authority
EP
European Patent Office
Prior art keywords
bourneville
treatment
tuberous sclerosis
antisense oligomers
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16876615.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3390635A1 (en
Inventor
Isabel AZNAREZ
Huw M. Nash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Stoke Therapeutics Inc
Original Assignee
Cold Spring Harbor Laboratory
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory, Stoke Therapeutics Inc filed Critical Cold Spring Harbor Laboratory
Publication of EP3390635A1 publication Critical patent/EP3390635A1/en
Publication of EP3390635A4 publication Critical patent/EP3390635A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16876615.2A 2015-12-14 2016-12-14 Antisense oligomers for the treatment of a tuberous sclerosis complex Withdrawn EP3390635A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267212P 2015-12-14 2015-12-14
PCT/US2016/066705 WO2017106375A1 (en) 2015-12-14 2016-12-14 Antisense oligomers for treatment of tuberous sclerosis complex

Publications (2)

Publication Number Publication Date
EP3390635A1 EP3390635A1 (en) 2018-10-24
EP3390635A4 true EP3390635A4 (en) 2019-05-01

Family

ID=59057534

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16876615.2A Withdrawn EP3390635A4 (en) 2015-12-14 2016-12-14 Antisense oligomers for the treatment of a tuberous sclerosis complex

Country Status (4)

Country Link
EP (1) EP3390635A4 (enrdf_load_stackoverflow)
JP (2) JP7051683B2 (enrdf_load_stackoverflow)
CA (1) CA3005131A1 (enrdf_load_stackoverflow)
WO (1) WO2017106375A1 (enrdf_load_stackoverflow)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2963288A1 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
CA3005256A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN110446785B (zh) 2017-01-23 2024-04-26 瑞泽恩制药公司 Hsd17b13变体及其应用
MX2019012169A (es) 2017-04-11 2019-12-11 Regeneron Pharma Ensayos para evaluar la actividad de moduladores de miembros de la familia de hidroxiesteroide (17-beta) deshidrogenasa (hsd17b).
ES2965696T3 (es) 2017-08-25 2024-04-16 Stoke Therapeutics Inc Oligómeros antisentido para el tratamiento de afecciones y enfermedades
SG11202003254SA (en) 2017-10-11 2020-05-28 Regeneron Pharma Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
CN112020556A (zh) 2018-03-21 2020-12-01 瑞泽恩制药公司 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法
JP2021523227A (ja) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． コレステリルエステル蓄積症の処置のための方法及び組成物
WO2021034985A1 (en) * 2019-08-19 2021-02-25 Stoke Therapeutics, Inc. Compositions and methods for modulating splicing and protein expression
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc Opa1 antisense oligomers for treatment of conditions and diseases
EP4560019A1 (en) * 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions
EP4560020A1 (en) * 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043561A2 (en) * 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
US20120252877A1 (en) * 2009-08-14 2012-10-04 Theramind Research, Llc Methods and compositions for treatment of tuberous sclerosis complex
WO2015035091A1 (en) * 2013-09-04 2015-03-12 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna decay
WO2016054615A2 (en) * 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2017106382A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of central nervous system diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179038A1 (en) * 2009-09-08 2012-04-27 Lab Corp America Holdings Compositions and methods for diagnosing autism spectrum disorders
GB201410693D0 (en) * 2014-06-16 2014-07-30 Univ Southampton Splicing modulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043561A2 (en) * 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
US20120252877A1 (en) * 2009-08-14 2012-10-04 Theramind Research, Llc Methods and compositions for treatment of tuberous sclerosis complex
WO2015035091A1 (en) * 2013-09-04 2015-03-12 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna decay
WO2016054615A2 (en) * 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2017106382A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of central nervous system diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Hit details for GSN:ASQ71657", 27 April 2020 (2020-04-27), XP055689536, Retrieved from the Internet <URL:http://ibis.internal.epo.org/exam/hitDetails.jsp?id=246015429> [retrieved on 20200427] *
DATABASE EMBL [online] 13 February 2015 (2015-02-13), "Sequence 87385 from patent US 8673560.", XP055572821, retrieved from EBI accession no. EM_PAT:HJ890926 Database accession no. HJ890926 *
DATABASE EMBL [online] 23 January 2014 (2014-01-23), "Sequence 84527 from Patent WO2013081755.", XP055572811, retrieved from EBI accession no. EM_PAT:JB952642 Database accession no. JB952642 *
DATABASE Geneseq [online] 13 November 2008 (2008-11-13), "Dual label detection probe, QF probe 1 5'_3'.", XP055572852, retrieved from EBI accession no. GSN:ARK21623 Database accession no. ARK21623 *
JANA KRALOVICOVA ET AL: "Optimal antisense target reducing INS intron 1 retention is adjacent to a parallel G quadruplex", NUCLEIC ACIDS RESEARCH, vol. 42, no. 12, 8 July 2014 (2014-07-08), pages 8161 - 8173, XP055211568, ISSN: 0305-1048, DOI: 10.1093/nar/gku507 *
JANA KRÁLOVICOVÁ ET AL: "Phenotypic consequences of branch point substitutions", HUMAN MUTATION, vol. 27, no. 8, 1 January 2006 (2006-01-01), US, pages 803 - 813, XP055689646, ISSN: 1059-7794, DOI: 10.1002/humu.20362 *
KRISTINA JÜLICH ET AL: "Mechanism-Based Treatment in Tuberous Sclerosis Complex", PEDIATRIC NEUROLOGY., vol. 50, no. 4, 1 April 2014 (2014-04-01), NL, pages 290 - 296, XP055572991, ISSN: 0887-8994, DOI: 10.1016/j.pediatrneurol.2013.12.002 *
MAYER K ET AL: "Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, AMSTERDAM, NL, vol. 1502, no. 3, 15 November 2000 (2000-11-15), pages 495 - 507, XP027370242, ISSN: 0925-4439, [retrieved on 20001115] *
See also references of WO2017106375A1 *

Also Published As

Publication number Publication date
CA3005131A1 (en) 2017-06-22
JP2022088533A (ja) 2022-06-14
JP2019500350A (ja) 2019-01-10
WO2017106375A1 (en) 2017-06-22
JP7051683B2 (ja) 2022-04-11
EP3390635A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
EP3390635A4 (en) Antisense oligomers for the treatment of a tuberous sclerosis complex
EP3389671A4 (en) ANTISENSE OLIGOMERS FOR THE TREATMENT OF ALAGILLE SYNDROME
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3389782A4 (en) ANTISENSE OLIGOMERS FOR THE TREATMENT OF A POLYCYSTIC KIDNEY DISEASE
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3482506C0 (en) Processing relaxation for aperiodic csi-rs
GB201616202D0 (en) Antisense oligonucleotides for the treatment of eye deisease
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3380062A4 (en) COMPOSITIONS FOR TREATING THE HAIR
HUE051071T2 (hu) Kannabidiol felhasználása gumós szklerózis komplex kezelésére
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP3409744A4 (en) SURFACE TREATMENT AGENT
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
IL269735A (en) Antisense oligonucleotides for the treatment of stargardt disease
EP3431566A4 (en) SURFACE TREATMENT AGENT
EP3335041A4 (en) BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA
EP3349793A4 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA
EP3347032A4 (en) TREATMENT OF ASZITES
FR3039368B1 (fr) Procede de traitement cosmetique
EP3684933A4 (en) THIOMORPHOLINO-OLIGONUCLEOTIDES, FOR TREATMENT OF MUSCULAR DYSTROPHY
EP3365014A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180706

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190401

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/6883 20180101ALI20190326BHEP

Ipc: A61K 31/7088 20060101ALI20190326BHEP

Ipc: C12N 15/113 20100101AFI20190326BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1262746

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KRAINER, ADRIAN

Inventor name: NASH, HUW M.

Inventor name: AZNAREZ, ISABEL

17Q First examination report despatched

Effective date: 20200506

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230922

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240222